References
- Ghany MG , StraderDB, ThomasDL, Seeff LB; American Association for the Study of Liver Diseases: diagnosis, management, and treatment of hepatitis C: an update. Hepatology49(4) , 1335–1374 (2009).
- Liu CJ , ChuangWL, LeeCM et al.: Peginterferon α-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.Gastroenterology136(2) , 496–504 (2009).
- Liu CH , LiuCJ, LinCL et al.: Pegylated interferon-α-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial.Clin. Infect. Dis.47(10) , 1260–1269 (2009).
- Hadziyannis SJ , SetteH Jr, Morgan TR et al.: Peginterferon α-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med.140(5) , 346–355 (2004).
- Scott JD , GretchDR: Molecular diagnostics of hepatitis C virus infection: a systematic review.JAMA297(7) , 724–732 (2007).
- Poordad F , ReddyKR, MartinP: Rapid virologic response: a new milestone in the management of chronic hepatitis C.Clin. Infect. Dis.46(1) , 78–84 (2008).
- Davis GL , WongJB, McHutchisonJG, MannsMP, HarveyJ, AlbrechtJ: Early virologic response to treatment with peginterferon a-2b plus ribavirin in patients with chronic hepatitis C.Hepatology38(3) , 645–652 (2003).
- Fried MW , HadziyannisSJ, ShiffmanM, MessingerD, ZeuzemS: Rapid viral response is a more important predictor of sustained virological response (SVR) than genotype in patients with chronic hepatitis C virus infection.J. Hepatol.48(Suppl. 2) , 5A (2008).
- Chen PJ , HwangY, LinCG, WuYJ, WuLS: The genetic differences with whole genome linkage disequilibrium mapping between responder and non-responder in interferon-α and ribavirin combined therapy for chronic hepatitis C patients.Int. J. Immunogenet.35(2) , 153–157 (2008).
- Hwang Y , ChenEY, GuZJ et al.: Genetic predisposition of responsiveness to therapy for chronic hepatitis C.Pharmacogenomics7(5) , 697–709 (2006).
- Younossi ZM , BaranovaA, AfendyA et al.: Early gene expression profiles of patients with chronic hepatitis C treated with pegylated interferon-α and ribavirin.Hepatology49 , 763–774 (2009).
- Tsukada H , OchiH, MaekawaT et al.: A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C.Gastroenterology136(5) , 1796–1805 (2009).
- Wada M , MarusawaH, YamadaR et al.: Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients.J. Viral. Hepat.16(6) , 388–396 (2009).
- Hayashi K , KatanoY, HondaT et al.: Mutations in the interferon sensitivity-determining region of hepatitis C virus genotype 2a correlate with response to pegylated-interferon-α 2a monotherapy.J. Med. Virol.81(3) , 459–466 (2009).
- Muñoz de Rueda P , CasadoJ, PatónR et al.: Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses.J. Virol.82(13) , 6644–6653 (2008).